Insider Purchases: Inside the Buy
Tag: Clinical Trials
AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?
Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥